MARKET WIREStock Titan • 9h ago
Lexaria Bioscience Corp. SEC Filing (Oct 14, 2026)Stock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
Why LEXX Stock dropped -7.43% Today — RQD Quant Desk Flash
$3.49 -7.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.44
Lexaria Bioscience Corp. (LEXX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $7.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LEXX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LEXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Lexaria Bioscience Corp. (NASDAQ: LEXX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.49 (-7.43% 1D, market cap $7.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LEXX ranks #728 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LEXX compare to SNGX and MTVA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEXX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SNGX (Soligenix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M) and MTVA (MetaVia Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, LEXX leads on earnings multiple (N/A) while LEXX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LEXX?
▼
Per LEXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-08-31, CIK 0001348362), Lexaria Bioscience Corp. generated $705.9K in revenue (+52.0% YoY), -$11.9M in net income, and -$10.5M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.44 (-1.53%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LEXX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY LEXX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 70.3% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.27-20.5% Next Q
26
Q2 (-2Q)Grade E$2.60+12.3% Next Q
29
Q3 (-1Q)Grade E$2.92+19.5% Next Q
31
CurrentGrade E$3.49-8.7% Hist 90D α
34
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LEXX Turnaround Squeeze
While LEXX currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.13) and Max Pain ($3.66) forces dealer call-delta covering toward $22.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LEXX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LEXX Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LEXX Stock dropped -7.43% Today — RQD Quant Desk Flash
Lexaria Bioscience Corp. (LEXX) dropped -7.43% to $3.49, trading at 6% of its 52-week range ($2.43 – $21.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($2.43 – $21.6) with RSI-14 at 52.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.49 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 70.3% gross margin and $0 annual free cash flow.
Live LEXX Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 12h ago
Lexaria Bioscience Corp. (LEXX) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 15h ago
Lexaria Bioscience (LEXX) Advances Intellectual Property with NeGuruFocus report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 18h ago
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 21h ago
Lexaria tests its first oral tablet formula against WegovyStock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Nigeria • 1d ago
Lexaria Bioscience receives four patents for drug delivery technology By Investing.comInvesting.com Nigeria report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
LEXX 8-K & SEC Filings - Yahoo FinanceYahoo! Finance Canada report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
71% of survey respondents would prefer a daily pill to a weekly weight-loss shotStock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 5d ago
Lexaria Celebrates its 70th Patent Award* New patents awarded in the US, Canada, and Europe * IP protection for treatments for Epilepsy, Diabetes, and HypertensionKELOWNA, BC / ACCESS Newswire / October 28, 2026 / (Nasdaq:LEXX) (the "Company" or "Lexaria"), a
MARKET WIREYahoo • 12d ago
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on ScheduleKELOWNA, BC / ACCESS Newswire / October 21, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LEXX)
- ✓Walkthrough of LEXX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LEXX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -65.38%📐 HORIZONTAL RANGE
2026-11-02O $3.30H $3.77L $3.30C $3.49VOL 39.3K
RES: $16.63SUP: $1.30SMA50: $5.13SMA200: $8.92
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LEXX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +52.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LEXX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LEXX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LEXX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LEXX)
Health Care Rank #728 of 1016
⚔️ SNGX vs LEXX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LEXX vs. SNGX, MTVA, TCRT, KPRX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexaria Bioscience Corp. (LEXX) ranks #728 by composite RQD confidence (34/100, grade E) and #912 by equity capitalization ($7.9M). Within this direct 5-issuer industry benchmark cohort, LEXX leads on earnings valuation at N/A trailing P/E, while LEXX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SNGX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with LEXX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LEXX
ACTIVE
Lexaria Bioscience Corp. | E | 34/100 | — | 96.0% | -35.0% | -7.43% | $7.9M | Benchmark Subject |
| SNGX Soligenix Inc. | D- | 42/100 | — | — | -35.0% | -3.63% | $8.0M | /sngx-vs-lexx → |
| MTVA MetaVia Inc. | E | 31/100 | — | — | -35.0% | -5.88% | $7.8M | /mtva-vs-lexx → |
| TCRT Alaunos Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +3.18% | $7.8M | /tcrt-vs-lexx → |
| KPRX Kiora Pharmaceuticals Inc. | E | 30/100 | — | — | -35.0% | -11.36% | $7.8M | /kprx-vs-lexx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-08-31 • CIK 0001348362In its most recent audited fiscal period (FY2025, filed 2025-08-31), Lexaria Bioscience Corp. (LEXX) reported GAAP revenue of $705.9K (+52.0% vs. FY2024 revenue of $464.3K , and +212.1% cumulative change since FY2023) , GAAP net income of -$11.9M, operating cash flow of -$10.5M, and free cash flow of -$10.5M (-109.4% YoY). On the balance sheet, LEXX closed FY2025 with $6.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-08-31 | $705.9K | -$11.9M | -$10.5M | -$10.5M | $6.1M | — |
| FY2024 (FY) | 2024-08-31 | $464.3K | -$5.8M | -$5.0M | -$5.0M | $9.8M | — |
| FY2023 (FY) | 2023-08-31 | $226.2K | -$6.7M | -$5.9M | -$5.9M | — | — |
3. LEXX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LEXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Lexaria Bioscience Corp. (NASDAQ: LEXX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.49 (-7.43% 1D, market cap $7.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LEXX ranks #728 in composite RQD confidence.
How does LEXX compare to SNGX and MTVA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEXX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SNGX (Soligenix Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M) and MTVA (MetaVia Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, LEXX leads on earnings multiple (N/A) while LEXX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LEXX?
Per LEXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-08-31, CIK 0001348362), Lexaria Bioscience Corp. generated $705.9K in revenue (+52.0% YoY), -$11.9M in net income, and -$10.5M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LEXX trading relative to its 50-day, 200-day, and 52-week technical levels?
LEXX last traded at $3.49 (-7.43% on volume of 37,919 shares), positioning the stock -31.97% below its 50-day simple moving average ($5.13) and -60.87% below its 200-day simple moving average ($8.92). Across its 52-week range of $2.43 to $21.60, LEXX sits at the 5.5% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.05 to $3.93).
LEXX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LEXX stock moving today?
Why LEXX Stock dropped -7.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
LEXX — Lexaria Bioscience Corp.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:21Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, LEXX carries an RQD Score of 34 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 7 of 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns or free cash flow to shareholders. The whale 13F flow pillar scores 5 of 20 and the insider conviction pillar scores 5 of 20, both pointing to weak institutional and insider support in the rating model. The macro regime fit pillar scores 6 of 20 with a beta of 1.0. The forensic balance sheet pillar scores 11 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 4 of 9, and a Debt/Equity of 0.5. For a prospective investor evaluating the stock today, the rating's implication is that upside drivers would need to come from catalysts rather than from current earnings or cash generation, and that valuation rests on an unproven operating base with negative margins. The rating model's verdict is a caution signal, not a personalized recommendation.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-08-31) | $0.7M | $-11.9M | $-11.9M | N/A | $-10.5M | $4.3M | N/A |
| FY 2024 (filed 2024-08-31) | $0.5M | $-5.8M | $-5.8M | N/A | $-5.0M | N/A | N/A |
| FY 2023 (filed 2023-08-31) | $0.2M | $-6.5M | $-6.7M | N/A | $-5.9M | N/A | N/A |
Per the SEC financials, revenue rose from $0.2M in FY 2023 to $0.7M in FY 2025, while operating losses widened to $-11.9M in FY 2025. Per the market data, net margin is -60% and ROIC is -35%, confirming the company is not yet profitable. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4 of 9, with a Debt/Equity of 0.5. Cash of $4.3M is reported for FY 2025 against an FCF outflow of $-10.5M in the same year.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the most recent item is a Stock Titan report of an SEC filing dated Oct 14, 2026, flagged YELLOW under MARKET WIRE. A Yahoo! Finance Canada seasonal returns chart and a GuruFocus intellectual property item are also flagged YELLOW. A Benzinga item lists LEXX among health care stocks moving in after-market trading, flagged YELLOW. A Stock Titan report on an oral tablet formula tested against Wegovy is flagged GREEN under CATALYST, the only catalyst-category item. An Investing.com Nigeria report states the company received four patents for drug delivery technology, flagged YELLOW. Risk watch items include the widening operating loss and the negative FCF documented in the SEC financials. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the specific revenue sources behind the $0.7M FY 2025 revenue, and how much is recurring versus one-time?
- What is the reported EPS, debt balance, and cash position for FY 2024 and FY 2023, which the source data marks as N/A or not reported?
- What is the company's cash runway given the $-10.5M FY 2025 FCF outflow against $4.3M of cash?
- What are the status and commercial timing of the drug delivery patents and the oral tablet formula referenced in the news feed?
- What trailing and forward earnings or EV/EBITDA metrics apply, given that the P/E, EV/EBITDA, and EPS fields are unavailable?
LEXX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lexaria Bioscience Corp. (LEXX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 9h ago
Lexaria Bioscience Corp. SEC Filing (Oct 14, 2026) Stock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 12h ago
Lexaria Bioscience Corp. (LEXX) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 15h ago
Lexaria Bioscience (LEXX) Advances Intellectual Property with Ne GuruFocus report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 18h ago
12 Health Care Stocks Moving In Thursday's After-Market Session Benzinga report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 21h ago
Lexaria tests its first oral tablet formula against Wegovy Stock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 1d ago
Lexaria Bioscience receives four patents for drug delivery technology By Investing.com Investing.com Nigeria report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
LEXX 8-K & SEC Filings - Yahoo Finance Yahoo! Finance Canada report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
71% of survey respondents would prefer a daily pill to a weekly weight-loss shot Stock Titan report covering Lexaria Bioscience Corp. (LEXX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LEXX Bull vs. Bear Conversation Board — What's Your Call at $3.49?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LEXX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $3.32 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is LEXX (E • RQD 34/100) a Buy at $3.77?
Welcome to the LEXX (Lexaria Bioscience Corp.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.87 (-23.9%)
Spot @ $3.77 Pump the brakes on LEXX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on LEXX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Lexaria Bioscience Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.79 (+27.1%)
Spot @ $3.77 LEXX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on LEXX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.77 (52-wk range $2.43 - $21.60), any beat on forward guidance forces shorts and underweight funds to chase.